September 25, 2025 — TAXIS Pharmaceuticals today issued a statement in response to a new report from the Centers for Disease Control and Prevention (CDC), published in the Annals of Internal Medicine on September 23. The CDC report highlights a dramatic increase in infections caused by a dangerous form of drug-resistant bacteria: NDM-producing carbapenem-resistant Enterobacterales (NDM-CRE).

Between 2019 and 2023, the report notes, NDM-CRE infections surged by over 460% in the United States. These infections — including pneumonia, bloodstream infections, urinary tract infections, and wound infections — are extremely difficult to treat, often deadly, and can spread rapidly in healthcare settings. Detection is also problematic, as many clinical laboratories lack the capacity to identify these pathogens.

NDM-CRE, like many antibiotic-resistant pathogens, poses a critical public health threat. These infections are resistant to nearly all available antibiotics, spread easily without stringent infection control measures, and are associated with high rates of morbidity and mortality.

TAXIS Pharmaceuticals is steadfast in its mission to develop first-in-class therapeutics that address the root causes of antimicrobial resistance (AMR) — with the goal of preventing future outbreaks like this and saving lives.

“The era of pharmaceutical companies developing ‘me-too’ antibiotics must come to an end,” said Gregory G. Mario, MBA, President and CEO of TAXIS Pharmaceuticals. “It’s not working — and it’s not enough. We need bold, coordinated action between public and private stakeholders to foster true innovation and combat antibiotic resistance. Millions of lives are at risk.”

TAXIS is advancing a robust pipeline of investigational therapies that target the fundamental mechanisms bacteria use to survive and evade current treatments — disrupting their cellular infrastructure and weakening the core systems that drive AMR.

TAXIS’ investigational pipeline includes:

  • FtsZ Inhibitors – Targeting the bacterial protein FtsZ to disrupt cell division and inhibit bacterial growth.
  • Dihydrofolate Reductase Inhibitors (DHFRIs) – Blocking dihydrofolate reductase, an enzyme essential for DNA and RNA synthesis, halting bacterial replication.
  • Efflux Pump Inhibitors – Preventing bacteria from expelling antibiotics, thereby enhancing the effectiveness of existing treatments.

“Without solutions that address the root causes of antimicrobial resistance, we are fighting a losing battle,” Mario added. “This isn’t hyperbole — without effective antibiotics, modern medicine is at risk of collapse. The CDC’s new report is a clear warning signal.”

TAXIS Pharmaceuticals welcomes partnerships with investors, research institutions, pharmaceutical companies, and other stakeholders committed to fighting antimicrobial resistance through innovation and collaboration.

For more information or to explore partnership opportunities: https://taxispharma.com/contact/

Media Contact:
Jennifer Ringler, MS
jringler@readhealthy.net
973-647-5004